23 Dec Most significant clincal trials of 2024

By Abigail Beaney, Clinical Trials Arena

From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure prophylaxis (PrEP) drugs, 2024 has been a busy year in the clinical trial space.

While many drugs have hailed positive data, sending stock prices soaring, others have failed to show benefit, with companies terminating the development of some highly anticipated therapies.

According to GlobalData’s Pharmaceutical Intelligence Centre, most trials completed in 2024 were Phase I studies (40.92%), with the second highest completion in Phase II (36.28%). During 2024, 15.62% of trial completions were Phase III studies. In 2024, there were 7,089 completions, more than the 6,234 trials that completed in 2023. Read more…